product information and Health benefit, allergy, side effect, use for asthma and
February 15 2016
The New Zealand green-lipped mussel (Perna canaliculus) is the source of an extract with a product name of Lyprinol. Continuing medical trials propose that this green-lipped mussel extract may be helpful in the management of inflammatory diseases, arthritis and asthma. Results of clinical studies to date have been contradictory, but there is some evidence that mussel extracts have some anti-inflammatory capabilities, and may potentially be helpful in asthma and arthritis.
and osteoarthritis, joint health
Lyprinol has shown significant anti-inflammatory activity when given to animals and humans. When treated orally with Lyprinol, Wistar and Dark Agouti rats developed neither adjuvant-induced polyarthritis or collagen induced auto-allergic arthritis. This was achieved with doses less than NSAIDs, and 200 times less than other seed or fish oils. Lyprinol subfractions inhibited LTB4 biosynthesis by PMN in vitro, and PGE2 production by activated macrophages. Much of this AI activity was associated with omega-3 PUFAs and natural antioxidants [e.g. carotenoids]. In contrast to NSAIDs, Lyprinol is non-gastro toxic in disease-stressed rats at 300 mg/kg p.o., and does not affect platelet aggregation [human, rat]. Clinical studies, either controlled or randomized, have demonstrated very significant anti-inflammatory activity in patients with osteoarthritis, rheumatoid arthritis, asthma, and other inflammatory conditions. Lyprinol is a reproducible, stable source of bioactive lipids with much greater potency than plant/marine oils currently used as nutritional supplements to ameliorate signs of inflammation.
Lyprinol 50 mg pill, a unique, stabilized marine lipid
extract to provide nutritional support for healthy joint function.
Stabilized marine lipid extract for joint support*
Lyprinol Supplement sale and buy at a reliable internet ecommerce store
Another alternative is Joint Power Rx.
and research, what is is used for:
Lyprinol is a COX inhibitor in vitro
Total lipid extracts of Perna canaliculus (a bivalve marine mollusc native to New Zealand, commonly called the green-lipped mussel) and Mytilus edulis (commonly called the common blue mussel) moderately inhibit ovine COX-1 and COX-2 pure enzymes in vitro.
and reduction of breathing problems
Asthma is a chronic inflammatory disease of the airways mediated, at least in part, by leukotrienes and other lipid mediators. Experimental studies have shown that the lipid extract of New Zealand green-lipped mussel, Perna canaliculus, is effective in inhibiting 5'-lipoxygenase and cyclo-oxygenase pathways responsible for production of eicosanoids, including leukotrienes and prostaglandins. The aim of this study was to assess its effect on symptoms, peak expiratory flow (PEF) and hydrogen peroxide (H2O2) in expired breath condensate as a marker of airway inflammation in patients with steroid-naive asthma. Forty six patients with asthma received two capsules of Lyprinol or placebo b.i.d for 8 weeks. Each capsule of Lyrinol contained 50 mg omega-3 polyunsaturated fatty acids and 100 mg olive oil, whereas placebo capsules contained only 150 mg olive oil. There was a significant decrease in daytime wheeze, the concentration of exhaled H2O2 and an increase in morning PEF in the Lyprinol group compared to the placebo group. There were no significant side-effects. The authors conclude that Lyprinol, the lipid extract of New Zealand green-lipped mussel may have some beneficial effect in patients with atopic asthma.
Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA and DHA in inflammatory rheumatoid disorders.
Adv Ther. 2004.
This 12-week drug-monitoring study was conducted to evaluate the efficacy of Sanhelios Mussel Lyprinol Lipid Complex on 50 adult men and women with inflammatory rheumatoid arthritis. A total of 34 patients required drug therapy before and during the study. By the end of the study, 21 (62%) patients were able to reduce their dosage and 13 were able to terminate drug therapy. At the end of the treatment period, 38% were regarded symptom free, and the number of patients with severe pain decreased significantly from 60% at baseline to 25% at the completion of the trial. A significant effect was observed for each investigated parameter. The special combination was generally very well tolerated, with only one, nonserious adverse event (mild nausea) reported. Lyprinol supplement may therefore be considered an effective and well-tolerated component of treatment regimens for inflammatory rheumatoid arthritis.
Allergy, side effect
I had previously taken Lyprinol without problems but I think this time they gave me an allergy. I constantly itch around my arms. I stopped 2 days ago and the itching has stopped.
It is very difficult to know for sure whether Lyprinol is the cause. If your doctor approves you could not use it for the next week and then restart it at one capsule once. Wait a few days and if no itching gradually resume every other day. We have no way of knowing whether something else you took or ate or was exposed to was the cause of the itching or whether it was the Lyprinol. This is the firs time anyone has reported to us itching associated with this product.
I appreciate the information on your site. I have been told that when current supplies of Lyprinol run out, no one will be able to get them except for a new patent holder of the extract process.
A. We are in direct contact with the Lyprinol manufacturer and will see if it will remain on the market.
Q. Is Tyler the company that has the patented process
for extracting the Lyprinol product?
A. It doesn't say on the bottle, other than that it's a patented process distributed by Lyrinol USA.